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Early clearance of Chikungunya 
virus in children is associated with a 
strong innate immune response
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Chikungunya fever (CHIKF) is a global infectious disease which can affect a wide range of age groups. 
The pathological and immunological response upon Chikungunya virus (CHIKV) infection have been 
reported over the last few years. However, the clinical profile and immune response upon CHIKV 
infection in children remain largely unknown. In this study, we analyzed the clinical and immunological 
response, focusing on the cytokine/chemokine profile in a CHIKV-infected pediatric cohort from 
Sarawak, Malaysia. Unique immune mediators triggered upon CHIKV infection were identified 
through meta-analysis of the immune signatures between this pediatric group and cohorts from 
previous outbreaks. The data generated from this study revealed that a broad spectrum of cytokines/
chemokines is up-regulated in a sub-group of virus-infected children stratified according to their 
viremic status during hospitalization. Furthermore, different immune mediator profiles (the levels 
of pro-inflammatory cytokines, chemokines and growth and other factors) were observed between 
children and adults. This study gives an important insight to understand the immune response of CHIKV 
infection in children and would aid in the development of better prognostics and clinical management 
for children.
Chikungunya fever (CHIKF) is an acute illness caused by the alphavirus Chikungunya virus (CHIKV). 
Transmitted by Aedes mosquitoes, clinical manifestations include an abrupt high fever, rashes, myalgia and 
arthralgia that will appear after an incubation period of 3–7 days. However, chronic and incapacitating arthralgia 
can persist for months to years1. CHIKV was first identified in 1953 during a dengue-like epidemic in Tanzania, 
and outbreaks of CHIKF have been documented in Africa and South East Asia throughout 1960s–1990s1–3. Since 
2005, CHIKV has caused outbreaks of an unprecedented magnitude in La Réunion with more than a third of 
its population infected4,5. Over 1.4 million cases have also occurred in India, South East Asia, and islands in 
the Pacific between 2006 and 20126–9. CHIKV has since spread to the Caribbean islands in late 201310, and as of 
November 2015, 8,275 laboratory-confirmed cases have been reported from these areas (http://www.cdc.gov/chi-
kungunya/geo/united-states-2015.html). With the worldwide increased spread of the Aedes mosquitoes, CHIKV 
remains a major threat to public health. Thus, with no available licensed vaccine or specific treatments, CHIKV 
can present a social and economic burden to affected communities.
Studies on CHIKF pathogenesis have revealed that CHIKV infection induced a wide range of cytokines, 
chemokines and growth factors11,12. Higher levels of IL-1β and IL-6, and lower level of RANTES were also linked 
to severe CHIKF11. Systematic meta-analysis has also revealed the immune signatures in patients from different 
CHIKF cohorts during the 2007–2010 outbreaks across different geographic locations13. CHIKV infection affects 
all age groups. However, studies on CHIKV-induced immune mediators across cohorts have been limited to adult 
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patients. Although CHIKV infections in children have been reported14–16, documentation remained limited to 
clinical descriptions with no information on the immune response. Symptoms such as high fever, rash, seizures, 
and weight loss were reported in infected neonates and infants14–16. Interestingly, although severe arthralgia and 
arthritis did occur in children, it was uncommon and usually resolved during the acute phase of disease16.
In this study, we studied the immune response of CHIKV infection by examining the disease manifestations 
and measuring the circulatory immune mediators during acute disease in a cohort of 86 children under the age 
of 12. Multiplex-microbead immunoassays were done and meta-analysis was further performed together with all 
available data from 2009 to 2014 relating to acute CHIKV infection in adults to identify unique immune markers 
explaining the different clinical manifestations between children and adults. Interestingly, a differential pattern 
was identified in the immune mediator response between pediatric patients with early viral clearance and those 
with prolonged viremia and joint pain.
Results
Clinical manifestations of a CHIKF pediatric cohort. Between October 2009 and March 2010, 108 
children were recruited for this study based on their presenting symptoms during hospital admission (Table 1). 
Patients’ admission sera (median sampling day was 1 day post illness onset) were subjected to virus isolation and 
tested by CHIKV-specific PCR test. IgM serology was performed to test for DENV infection17. Eighty-six children 
were confirmed CHIKV positive with a median age of 4.86 years, ranging from 1 week to 11 years old. The length 
of stay was between 2–8 days. The most reported clinical manifestations of this cohort were fever, joint pain, facial 
flushing, skin rash (mostly erythematous, with some cases of maculopapular rash), chills, and headache (Table 1). 
Many of these children also suffered from loss of appetite and were not drinking well (Table 1).
Of these 86 pediatric patients, blood samples were obtained from 64 individuals during both hospital admis-
sion and at discharge (i.e. paired samples). CHIKV was still detectable by virus isolation in 34 patients at dis-
charge and thus classified as the prolonged viremia group (Table 1). The other 30 children with no detectable 
CHIKV by PCR at discharge were classified as early viral clearance group (Table 1). The remaining 22 CHIKF 
pediatric patients were classified as the unpaired sample group as blood samples were obtained during hospital 
admission only.
Profiles of immune mediators in children. We next characterized the immune mediator profiles of acute 
serum samples collected from the 86 children using a multiplex-microbead immunoassay11. Samples from 64 
adult Singapore CHIKF patients18,19 and 8 healthy adults were included in the analysis. Both groups of patients 
represent the population in South-East Asia, and no major difference in disease severity was observed. The pedi-
atric cohort induced a higher level of several immune mediators when compared to the adult cohort (Fig. 1). 
Pro-inflammatory cytokines: TNF-β , TRAIL, IL-5, GRO-α , IL-18, IFN-α 2, IL-2Ra; chemokines: MIF, MIG, 
MCP-3, G-CSF; growth and others: SCGF-β , M-CSF, HGF, SCF, LIF, IL-3 were significantly higher in children 
compared to adults (Fig. 1). However, IL-1β ; RANTES, SDF-1α , and β -NGF were significantly lower in children 
(Fig. 1). This observation suggests that an active production of immune mediators in children could provide a 
strong anti-viral environment during acute disease that could result in a better clinical outcome.
CHIKV-positive (n = 86)a
Early clearance 
(n = 30)
Prolonged viremia 
(n = 34)
Unpaired samples 
(n = 22)
Age, median (range), years 3.69 (0.42–11.64) 5.93 (0.16–11.85) 5.64 (0.01–11.84)
Gender ratio (boy/girl) 1.14 1.83 1.44
Race, n (%), Chinese 8 (26.7) 8 (23.5) 6 (27.3)
Iban 13 (43.3) 20 (58.8) 11 (50)
Malay 4 (13.3) 2 (5.9) 5 (22.7)
Others 5 (16.7) 4 (11.8) 0 (0)
Length of admission, 
median (range), days 3 (3–6) 3 (2–8) 4 (2–7)
Fever, n (%) 30 (100) 34 (100) 22 (100)
Chills, n (%) 14 (46.7) 18 (52.9) 12 (54.5)
Facial flushing, n (%) 16 (53.3) 27 (79.4) 15 (68.2)
Skin rash, n (%) 15 (50) 20 (58.8) 13 (59.1)
Headacheb, n (%) 13 (52) 12 (52.2) 7 (31.8)
Joint painb, n (%) 14 (56) 21 (91.3) 11 (50)
Loss of appetite, n (%) 24 (80) 25 (73.5) 16 (72.7)
Not drinking, n (%) 23 (76.7) 22 (64.7) 14 (63.6)
Table 1.  Demographic and characteristics of pediatric patients admitted to Sibu hospital between 
September 2009 and March 2010 for CHIKF. aCHIKV-positive were confirmed by PCR and/or virus isolation. 
bClinical ‘pain’ parameters that were only recorded in patients age 2 years and older.
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Figure 1. Children have higher levels of immune mediators than adults. Levels of Immune mediators (Pro-
inflammatory cytokines, anti-inflammatory cytokines, chemokines and growth and other factors) during acute 
CHIKV infection (samples collected during the admission stage of hospitalization) from two groups of patients 
(86 children and 64 adults) were analyzed and presented in heat map of normalized scores. In the heat map 
presentation, the immune mediator concentrations were scaled between 0 and 1 for each measured immune 
mediator and then the average scaled value computed for each group. Blue colors represent the lowest average 
scaled value while pink colors represent the highest average scaled value. Immune mediators levels of healthy 
adults (n = 8) were included as reference point. Differences between the two groups were analyzed using Mann-
Whitney U-test, with Bonferroni correction.
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Meta-analysis of common immune mediators between adults and children. The levels of 
immune mediators in adult patients with CHIKV infection have been widely reported from geographically 
distinct cohorts and compared systematically13. To compare the current data set in this study, a meta-analysis 
was performed. Source of samples, classification of immune mediators, study selection, study exclusion, and 
meta-analysis were done as described13. Table 2 shows an overview of the expression profiles of all immune medi-
ators that demonstrated a significant up-regulation relative to the healthy controls. Twenty-six factors: IL-2Ra, 
IL-6, IFN-α 2, IL-16, IL-7, IL-15, IL-12, IL-18, GM-CSF, IL-1ra, IL-10, MCP-1, IP-10, MIG, SDF-1α , G-CSF 
(P < 0.01); IL-12p40, TNF-α , IL-2, IFN-γ , IL-17, IL-4, MIP-1β , RANTES, MIP-1α , FGF-β (P < 0.05) were found 
to be age-independent factors for acute CHIKV infection. Forest plots showing the significant elevated immune 
mediators are summarized in Supplementary Figs S1–S4. Pro-inflammatory cytokines remain as the dominant 
signature for acute CHIKV infection (> 50%) within the four categories of immune mediators. This suggests that 
a common pattern of immune signature exists from CHIKV infection across ages and cohorts.
Differential immune mediators profiles in different viremic conditions in children. The CHIKF 
pediatric patients were further classified based on the viremic condition during the hospitalization period, into 
early viral clearance and prolonged viremia groups (Table 1). Surprisingly, a distinct profile was observed in the 
immune mediators between these two groups (Fig. 2). Analyzes revealed that higher levels of pro-inflammatory 
cytokines, chemokines, growth and other factors were obtained in the early viral clearance group (Fig. 2). Profiles 
of pro-inflammatory cytokines, IL-12p40, IL-1α , TNF-β , TRAIL, GM-CSF, and IFN-γ were shown to be sig-
nificantly higher in the early viral clearance group than in the prolonged viremia group (Fig. 2). Interestingly, 
the anti-inflammatory cytokine IL-10 was also significantly higher in the early viral clearance group (Fig. 2). 
Profiles of chemokines, CTACK, SDF-1α , IP-10, MCP-1 and MIP-1β were significantly higher in the early viral 
clearance group, while MCP-3 and MIP-1α were significantly higher in the prolonged viremia group (Fig. 2). 
Comparatively, SCGF-β , PDGF-BB and VEGF levels were significantly higher in early viral clearance group, while 
LIF level was significantly lower in early viral clearance group (Fig. 2). All other markers were not significantly 
different between the two groups (data not shown).
To further determine if any association exists between clinical manifestations with viral clearance, the per-
centage of patients with different clinical parameters were compared. Our analysis revealed that facial flush-
ing and joint pain occurred more frequently in children in the prolonged viremia group (Table 1 and Fig. 3A). 
Interestingly, the manifestation of joint pain in children was associated with lower levels of the pro-inflammatory 
cytokine GM-CSF (Fig. 3B) observed during acute CHIKV infection.
Discussion
CHIKF affects patients of different age groups and it is important to obtain a holistic view of CHIKV-induced 
immune mediators from multiple cohorts of all ages. Here, the profiles of several immune regulators in 
CHIKV-infected pediatric patients were characterized through systematic meta-analysis in order to better define 
CHIKV infection in children. Clinical features such as the loss of appetite and not drinking are often linked to 
CHIKV infection. However, these are constitutional symptoms commonly observed in many bacterial and viral 
infections as well as non-communicable diseases in children20. Joint-specific arthralgia (specific areas includ-
ing knee, wrist and small joint of the hands and feet) is a well-characterized hallmark of CHIKF during the 
acute phase of disease13. Interestingly, a significantly higher percentage of children who suffered from prolonged 
viremia experienced joint pain. To our knowledge, this is the first study showing a clear association between the 
viremic phase with arthralgia in CHIKV-infected patients.
Pro-inflammatory 
cytokines (P-value)
Anti-inflammatory 
cytokines (P-value) Chemokines (P-value)
Growth and other 
factors (P-value)
IL-2Ra (6.57E-16) IL-1ra (1.57E-04) MCP-1 (1.20E-08) FGF-β (1.88E-02)
IL-6 (4.59E-07) IL-10 (5.16E-04) IP-10 (5.06E-07)
IFN-α 2 (1.46E-06) IL-4 (3.54E-02) MIG (5.31E-05)
IL-16 (8.83E-06) SDF-1α (2.07E-04)
IL-7 (3.48E-05) G-CSF (3.24E-03)
IL-15 (6.05E-05) MIP-1β (1.31E-02)
IL-12 (1.11E-03) RANTES (2.34E-02)
IL-18 (2.75E-03) MIP-1α (4.75E-02)
GM-CSF (7.20E-03)
IL-12p40 (1.79E-02)
TNF-α (1.81E-02)
IL-2 (2.30E-02)
IFN-γ (3.07E-02)
IL-17 (3.14E-02)
Average percentage of 
elevated immune mediators 
from each subcategory (%)
54 11 31 4
Table 2.  Signature of immune mediators in patients with acute CHIKV infection.
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Figure 2. Differentially-regulated immune mediators profiles in children. Levels of immune mediators 
during acute CHIKV infection (samples collected during the admission stage of hospitalization) were 
analyzed. Patients were grouped into early viral clearance (n = 30), and prolonged viremia (n = 34) groups and 
compared and presented in heat map of normalized scores. In the heat map presentation, the immune mediator 
concentrations were scaled between 0 and 1 for each measured immune mediator and then the average scaled 
value computed for each group. Blue colors represent the lowest average scaled value while pink colors represent 
the highest average scaled value. Differences between the two groups were analyzed using Mann-Whitney  
U-test, with Bonferroni correction.
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Clinicians at the Sibu hospital observed that the overall clinical outcome observed for the majority of children 
in this cohort is milder than adults. Arthralgia observed in the majority of children was relatively short-lived, mild 
and rapidly resolved with paracetamol, which was used to provide simple analgesia and treat high fever in the 
study cohort. At the clinic, the cardinal signs of arthralgia (redness, swelling and increased warmth of the affected 
joint) were only observed in approximately 20% of the CHIKV-positive children. Indeed, the parents of affected 
children were more concerned about the high body temperature and skin rashes than the morbidity of arthral-
gia. Based on the meta-analysis data, different patterns were found in the immune factors between children and 
adults. Specifically, the levels of pro-inflammatory cytokines such as IL-18, IFN-α 2 and IL-2Ra were much higher 
in children. This is interesting, as children have been reported in various studies to have low basal cytokines levels 
under healthy physiological conditions, although some cytokines have more complex age-dependent profiles21. 
Therefore, the high fold increase in some of the critical immune mediators such as IL-18, IFN-α 2, IL-2Ra, GRO-α , 
MIF, MIG, MCP-3, SCGF-β , M-CSF, HGF, SCF, LIF and IL-3 from healthy to disease state could play a role in 
influencing disease severity in children22. This is in contrast to adults where the basal levels of immune mediators 
are generally higher, due to prior exposures to a broad range of environmental factors23, infections24, and ageing25.
IL-18 is one of the most important pro-inflammatory cytokines in host defense against infection, and in NK 
cells activation26. It has been established that NK cells are involved in CHIKV infections27. Therefore, NK cells 
may have a more prominent role in inflammation and homeostasis in children. Moreover, there is mounting evi-
dence that IL-18 could be a novel therapeutic target in treating inflammatory disease28. On the other hand, IL-2Ra 
is an important indicator of T cell activation29 and a marker for regulatory T cells (Tregs). More recently, selec-
tive expansion of Tregs by the JES6-1 anti-IL-2 antibody complex has been shown to ameliorate experimental 
CHIKV-infected joint pathology30. Therefore, the higher level of IL-2Ra in children may indicate a larger number 
of Tregs in children that could alleviate joint inflammation and result in a better disease outcome30,31.
It is surprising that the manifestation of joint pain in children associated with lower levels of the 
pro-inflammatory cytokine GM-CSF. Since GM-CSF is often described as a key component in experimental 
osteoarthritis and pain development32 in the IL-1β pathway32. The high levels of GM-CSF observed here could 
contribute to the control of viremia through its pro-inflammatory effect and this in turn could result in an early 
viral clearance in this subgroup of children. This raises an interesting point as the level of GM-CSF could have 
a role in regulating clinical outcomes such as the development of joint pain during the acute phase of CHIKV 
infection even without engaging the IL-1β pathway.
Previous meta-analysis studies based on CHIKV-infected adult cohorts have defined the immune signature 
of mediators induced in patients suffering from acute CHIKV infection13. With the inclusion of new data from 
this pediatric cohort, a new immune signature of acute CHIKV immune mediators was derived. All categories 
of immune mediators exist in similar proportions, indicating that regardless of age, acute CHIKV infection is 
driven mainly by an inflammatory response that will in turn exert an anti-viral activity. Once again, IFN-α is sig-
nificantly up-regulated during the acute phase of disease (Fig. 1) and could be a specific indicator to distinguish 
between CHIKV and DENV infections as the up-regulation of IFN-α is absent in DENV infection13.
Taken together, this is the first systematic analysis of immune mediators reported in CHIKV-infected children. 
The addition of this new cohort redefines the significant immune signatures that can be extended to derive a new 
set of biomarkers specific to acute CHIKV infection in young children (IL-18, IL-2Ra, IFN-α 2, G-CSF and MIG) 
and adult patients (SDF-1α , RANTES). Information from the recent disease outbreaks in the Americas (from 
Caribbean islands to South America) will be important to provide valuable data to further validate the robust-
ness of this new immune signature and how they can be used for differentiating CHIKV-infected patients from 
non-CHIKV infected patients regardless of age.
Methods
Ethical Approval – Children cohort from Sarawak (2009) and Adult cohort from Singapore 
(2008). Written informed consent was obtained from all participants, participants’ parents or legal guardians 
Figure 3. Higher proportions of patients with prolonged viremia suffered from joint pain. (A) Proportions 
of patients with joint pain within early viral clearance (n = 25) and prolonged viremia (n = 23) group were 
analyzed using two-sided Fisher’s exact test. GM-CSF levels were higher in patients without joint pain.  
(B) Comparison of cytokine levels between patients with (n = 35) or without joint pain (n = 13). Levels are 
expressed in pg/mL, horizontal lines represent median values. Two-tailed, Mann-Whitney U-tests with 
Bonferroni correction were used to evaluate differences between the two groups of patients.
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and study was conducted according to Declaration of Helsinki principles. For the pediatric cohort, the clini-
cal study and the use of human samples was approved by the Malaysian Ministry of Health’s Institute Review 
Board (KKM/NIHSEC/08/0804/P07-197). For the adult CHIKF cohort, the study was approved by the National 
Healthcare Group’s Domain-Specific Ethics Review Board (DSRB Reference No. B/08/026). The methods were 
carried out in accordance with the approved guidelines.
Patients and Serum Collection. Sixty-four adult patients admitted with acute CHIKF to the 
Communicable Disease Centre at Tan Tock Seng Hospital in Singapore during the outbreak from 1 August to 
23 September 2008 were included in this study18,19. Acute phase plasma specimens were collected at median 4 
days post-illness onset (PIO). Clinical features definition and clinical samples were as described previously18,19. 
Children presented with fever or a history of fever lasting less than 7 days, one or more of the following clinical 
features: skin rashes, joint pain or muscle pain, and a negative blood film for malaria parasite with no appar-
ent focal infection such as pneumonia or urinary tract infection were included into the study after obtaining 
informed consent from the parents or guardians. All children did not receive any medication before collection of 
the first blood sample and samples were taken on the day of hospital admission and at hospital discharge.
PCR and virus isolation. All clinical specimens were screened for CHIKV using either a published33 or 
in-house (data not shown) real time RT-PCR assay. Viruses were isolated using either the C6/36 mosquito or 
Vero cell lines. A total of 10 Sarawak partial E1 gene nucleotide sequences from the 2009 outbreak generated in 
this study were analyzed together with reference sequences obtained from GenBank. A maximum likelihood 
phylogenetic tree was prepared and edited using the MEGA v6.06 software34. To assess the robustness of the 
tree, a bootstrap re-sampling analysis of 1000 pseudo-replicate trees was performed. A preliminary phylogenetic 
investigation of an approximately 500 base-pair nucleotide region of the E1 gene identified the Sarawak CHIKV 
as part of the East/Central/South African genotype (Supplementary Fig. S5).
Multiplex-Microbead Immunoassay. Serum levels of immune mediators were measured using the 
Bio-Plex Pro™ human cytokine 21-plex (CTACK, GRO-α , HGF, IFN-α 2, IL-12p40, IL-16, IL-18, IL-1α , IL-2Ra, 
IL-3, LIF, M-CSF, MCP-3, MIF, MIG, SCF, SCGF-β , SDF-1α , TNF-β , TRAIL, β -NGF) and 27-plex (Basic-FGF, 
Eotaxin, G-CSF, GM-CSF, IFN-γ , IL-10, IL-13, IL-15, IL-17A, IL-1β , IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, 
IL-9, IP-10, IL-12p70, MCP-1, MIP-1α , MIP-1β , PDGF-BB, RANTES, TNF-α , VEGF) immunoassay kits 
(Bio-Rad) according to the manufacturer’s instruction. Briefly, magnetic beads were aliquoted in 96-well plates 
followed with addition of standards and sera from patients and control subjects. After an incubation period, plates 
were washed using a magnetic wash station according to manufacturer’s instructions, followed with addition of a 
detection antibody. Plates were incubated for a further 30 minutes and washed, followed with a final incubation 
of 10 minutes in the presence of streptavidin-PE. Results were acquired using the flexMAP™ 3D (Luminex corp.) 
with Luminex xPONENT® software, based on standard curves plotted through a 5-parameter logistic curve 
setting.
Meta-analysis. Meta-analysis (including search strategy, study selection, data extraction for comparison and 
statistical testing) was done previously13, except for the inclusion of the current data from the two cohorts. Levels 
of immune mediators from healthy children were obtained from published studies21,35–39.
Data Analysis. Continuous variables were compared between different patient groups using non-parametric 
Mann-Whitney U test (2-tailed) analysis, with Bonferroni correction. P-values of < 0.05 were considered statisti-
cally significant. Hierarchical clustering was done using TM4-MeV40.
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